Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis

Description

This is an open label study looking at rifaximin therapy for the treatment of microscopic (collagenous or lymphocytic) colitis.

Conditions

Microscopic Colitis

Talk to us

Study Overview

On this page

Study Details

Study overview

This is an open label study looking at rifaximin therapy for the treatment of microscopic (collagenous or lymphocytic) colitis.

Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis

Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis

Condition
Microscopic Colitis
Intervention / Treatment

-

Contacts and Locations

Evanston

NorthShore University HealthSystem, Evanston, Illinois, United States, 60201

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Collagenous colitis (CC) or lymphocytic colitis (LC) diagnosed on colon biopsies reviewed by 2 separate pathologists
  • * CC will be defined histologically to be the following: thickness of the collagenous subepithelial table \>10 micrometer using an ocular micrometer, inflammation in the lamina propria consisting of mainly lymphocytes and plasma cells, lack of crypt architectural distortion, and regenerative-appearing changes in the surface and/or crypt epithelium
  • * LC will be defined histologically to be the following: intraepithelial lymphocytes \>20 per 100 epithelial cells in the subjective area of highest lymphocyte density, inflammation in the lamina propria consisting of mainly lymphocytes and plasma cells, and regenerative-appearing changes in the surface and/or crypt epithelium
  • * Subjects in active flare, defined as \>3 watery/loose stools per day on \>4 / 7 days over \>4 weeks in the past 3 months.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Eugene F Yen, MD,

Eugene Yen, MD, PRINCIPAL_INVESTIGATOR, NorthShore University HealthSystem

Study Record Dates

2021-12